Clinical Safety, Toxicity, and Efficacy of Immunotherapies in Combination with Radiation Therapy-AM2018
This educational session provides a comprehensive review of the safety, toxicity, and efficacy of currently available commercial immunotherapies combined with radiation therapy. The session will be limited to immunotherapies in clinical use and we will not discuss experimental drugs or mechanisms. We will review the known side effects of approved immunotherapies currently in clinical use. We will then review the published safety and toxicity data of these immunotherapies in combination with radiation therapy. We will then review the published efficacy of these immunotherapies in combination with radiation therapy. This session will be especially usefull for community and academic clinicians as radiation is frequently being utilized concurrently with immunotherapies in the pallaitive and definitive setting on and off clinical trials.
This activity is available from January 3, 2019 through 11:59 p.m. Eastern time on January 2, 2021.
This activity was originally recorded at ASTRO’s 2018 Annual Meeting, October 22-24, 2018 in San Antonio, TX.
The meeting is designed to meet the interests of radiation oncologists, radiation oncology residents, medical oncologists and nurses.
- Define and identify the side effect profile and presenting symptoms of toxicities from immunotherapies.
- Identify the currently available safety and toxicity profile of radiation combined with immunotherapies.
- Charles Drake, MD, PhD is employed by Columbia University Medical Center and receives compensation/remuneration/funding from Dendreon, Janssen, Roche/Genentech, Lilly, Medimmune, Merck, Pierre Fabre, Bristol Myers Squibb, Agenus, Aduro Biotech, and holds ownership/investment interests in Potenza, Harpoon, Tizona, Kleo, and Compugen.
- Jonathan Schoenfeld, MD, MPhil, MPH is employed by Brigham and Women's Hospital, receives compensation/remuneration/funding from BMS, Merck, Tilos, and holds leadership positions at NCI Match Subprotocol Z1D and Translational PI.
- Andrew Sharabi, MD, PhD is employed by UC San Diego, Moores Cancer Center, receives compensation/remuneration/funding from Varian and AstraZeneca, and holds leadership positions at NCI G1 Therapeutics and Healthspan.
Additionally, the SA-CME Task Force and the CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.